Journal article
An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial
Abstract
OBJECTIVE(S): Central venous lines (CVLs) are major risk factors for venous thromboembolism (VTE) in children. The objective of PROTEKT was to determine if a low molecular weight heparin (reviparin-sodium) safely prevents CVL-related VTE.
STUDY DESIGN: This multi-center, open-label study, with blinded central outcome adjudication, randomized patients with new CVLs to twice-daily reviparin-sodium or standard care. The efficacy outcome was based …
Authors
Group TPS; Massicotte P; Julian JA; Gent M; Shields K; Marzinotto V; Szechtman B; Chan AK; Andrew M
Journal
Thrombosis Research, Vol. 109, No. 2-3, pp. 101–108
Publisher
Elsevier
Publication Date
January 2003
DOI
10.1016/s0049-3848(03)00099-9
ISSN
0049-3848